Symbols

AXSM

Axsome Therapeutics·NASDAQ

--(--)

AXSM fundamentals

AXSM Q4 2025 Earnings

Axsome Therapeutics (AXSM) released its earnings on Feb 23, 2026: revenue was 194.69M (YoY +63.93%), beat estimates; EPS was -0.56 (YoY +63.64%), beat estimates.

Revenue / YoY

194.69M

+63.93%

EPS / YoY

-0.56

+63.64%

Report date

Feb 23, 2026

AXSM Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 65% YoY to $196 million, driven by AUVELITY ($507 million, +74%), SUNOSI, and SYMBRAVO launch.
Pipeline Momentum: AUVELITY sNDA for Alzheimer's agitation (PDUFA April 30), AXS-12 narcolepsy NDA imminent, and AXS-17 epilepsy Phase II prep underway.
Commercial Expansion: AUVELITY sales force tripled to 600 reps; SYMBRAVO targeting 52% payer coverage.
Financial Efficiency: Net loss down 61% YoY to $28.6 million; cash balance $323 million for operational sustainability.
Strategic Differentiation: AXS-05's rapid onset and safety profile position it for leadership in MDD and ADA markets.

Earnings

EPS

Revenue

Revenue & Expenses

AXSM has released its 2025 Q4 earnings report, with revenue of 196.00M, reflecting a YoY change of 65.03%, and net profit of -28.56M, showing a YoY change of 61.88%. The Sankey diagram below clearly presents AXSM's revenue sources and cost distribution.

Key Indicators

Axsome Therapeutics (AXSM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Axsome Therapeutics (AXSM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Axsome Therapeutics (AXSM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Axsome Therapeutics (AXSM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown